Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity

Arthritis Care and Research

Volumn 66, Issue 2, 2014, Pages 190-196

  Tymms, Kathleen ^a   Zochling, Jane ^b   Scott, James ^c   Bird, Paul ^d   Burnet, Simon ^e   De Jager, Julien ^f   Griffiths, Hedley ^g   Nicholls, Dave ^h   Roberts, Lynden ⁱ   Arnold, Mark ^j   Littlejohn, Geoffrey ^k  

^a Canberra Rheumatology   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c Roche Products   (Australia)

^d Combined Rheumatology Practice ^*  (Australia)

^e QUEEN ELIZABETH HOSPITAL   (Australia)

^f Olser House   (Australia)

^g Barwon Rheumatology Service   (Australia)

^h Coast Joint Care ^*  (Australia)

ⁱ TOWNSVILLE HOSPITAL   (Australia)

^j Arthritis Specialist Centre   (Australia)

^k MONASH MEDICAL CENTRE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; COMORBIDITY; DAS28; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE SEVERITY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCULOSKELETAL PAIN; REMISSION; RHEUMATOID ARTHRITIS;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUSTRALIA; BLOOD SEDIMENTATION; CROSS-SECTIONAL STUDIES; DISABILITY EVALUATION; ELECTRONIC HEALTH RECORDS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84893349162     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22108     Document Type: Article

References (19)

1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
2. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
3. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
4. Sokka T, Hetland ML, Makinen H, Kautiainen H, Horslev-Petersen K, Luukkainen RK, et al, for the Questionnaires in Standard Monitoring of Patients With Rheumatoid Arthritis Group. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum 2008; 58: 2642-51.
5. Littlejohn G, Tymms KE,. Multi-centre, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control [abstract]. Arthritis Rheum 2010; 62 Suppl: S133.
6. Kievit W, van Hulst L, van Riel P, Fraenkel L,. Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: results from a choice-based conjoint analysis. Arthritis Care Res (Hoboken) 2010; 62: 842-7.
7. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
8. Fransen J, Creemers MC, Van Riel PL,. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004; 43: 1252-5.
9. Wolfe F, Michaud K,. Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. Arthritis Rheum 2007; 56: 2135-42.
10. Cannon GW, Mikuls TR, Hayden CL, Ying J, Curtis JR, Reimold AM, et al. Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. Arthritis Care Res (Hoboken) 2011; 63: 1680-90.
11. Landewe RB, van der Heijde DM,. Principles of assessment from a clinical perspective. Best Pract Res Clin Rheumatol 2003; 17: 365-79.
12. Barton JL, Imboden J, Graf J, Glidden D, Yelin EH, Schillinger D,. Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010; 62: 857-64.
13. Nicolau G, Yogui MM, Vallochi TL, Gianini RJ, Laurindo IM, Novaes GS,. Sources of discrepancy in patient and physician global assessments of rheumatoid arthritis disease activity. J Rheumatol 2004; 31: 1293-6.
14. Pincus T, Esther R, DeWalt DA, Callahan LF,. Social conditions and self-management are more powerful determinants of health than access to care. Ann Intern Med 1998; 129: 406-11.
15. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63: 573-86.
16. Aletaha D, Smolen JS,. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 2007; 21: 663-75.
17. Pincus T, Swearingen CJ, Bergman M, Yazici Y,. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol 2008; 35: 2136-47.
18. De Punder YM, Fransen J, Kievit W, Houtman PM, Visser H, van de Laar MA, et al. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology (Oxford) 2012; 51: 1610-7.
19. Aletaha D, Funovits J, Keystone EC, Smolen JS,. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007; 56: 3226-35.